Stephenson Rachel, Carnell Sonya, Johnson Nicola, Brown Robbie, Wilkinson Jennifer, Mundy Anthony, Payne Steven, Watkin Nick, N'Dow James, Sinclair Andrew, Rees Rowland, Barclay Stewart, Cook Jonathan A, Goulao Beatriz, MacLennan Graeme, McPherson Gladys, Jackson Matthew, Rapley Tim, Shen Jing, Vale Luke, Norrie John, McColl Elaine, Pickard Robert
Newcastle Clinical Trials Unit, Newcastle University, 1-2 Claremont Terrace, Newcastle upon Tyne, NE2 4AE, UK.
University College London Hospital, 235 Euston Road, London, NW1 2BU, UK.
Trials. 2015 Dec 30;16:600. doi: 10.1186/s13063-015-1120-4.
Urethral stricture is a common cause of difficulty passing urine in men with prevalence of 0.5 %; about 62,000 men in the UK. The stricture is usually sited in the bulbar part of the urethra causing symptoms such as reduced urine flow. Initial treatment is typically by endoscopic urethrotomy but recurrence occurs in about 60% of men within 2 years. The best treatment for men with recurrent bulbar stricture is uncertain. Repeat endoscopic urethrotomy opens the narrowing but it usually scars up again within 2 years requiring repeated procedures. The alternative of open urethroplasty involves surgically reconstructing the urethra, which may need an oral mucosal graft. It is a specialist procedure with a longer recovery period but may give lower risk of recurrence. In the absence of firm evidence as to which is best, individual men have to trade off the invasiveness and possible benefit of each option. Their preference will be influenced by individual social circumstances, availability of local expertise and clinician guidance. The open urethroplasty versus endoscopic urethrotomy (OPEN) trial aims to better guide the choice of treatment for men with recurrent urethral strictures by comparing benefit over 2 years in terms of symptom control and need for further treatment.
METHODS/DESIGN: OPEN is a pragmatic, UK multicentre, randomised trial. Men with recurrent bulbar urethral strictures (at least one previous treatment) will be randomised to undergo endoscopic urethrotomy or open urethroplasty. Participants will be followed for 24 months after randomisation, measuring symptoms, flow rate, the need for re-intervention, health-related quality of life, and costs. The primary clinical outcome is the difference in symptom control over 24 months measured by the area under the curve (AUC) of a validated score. The trial has been powered at 90% with a type I error rate of 5% to detect a 0.1 difference in AUC measured on a 0-1 scale. The analysis will be based on all participants as randomised (intention-to-treat). The primary economic outcome is the incremental cost per quality-adjusted life year. A qualitative study will assess willingness to be randomised and hence ability to recruit to the trial.
The OPEN Trial seeks to clarify relative benefit of the current options for surgical treatment of recurrent bulbar urethral stricture which differ in their invasiveness and resources required. Our feasibility study identified that participation would be limited by patient preference and differing recruitment styles of general and specialist urologists. We formulated and implemented effective strategies to address these issues in particular by inviting participation as close as possible to diagnosis. In addition re-calculation of sample size as recruitment progressed allowed more efficient design given the limited target population and funding constraints. Recruitment is now to target.
ISRCTN98009168 Date of registration: 29 November 2012.
尿道狭窄是男性排尿困难的常见原因,患病率为0.5%;在英国约有62,000名男性受此影响。狭窄通常位于尿道球部,会导致诸如尿流减少等症状。初始治疗通常采用内镜下尿道切开术,但约60%的男性在2年内会复发。对于复发性球部尿道狭窄男性的最佳治疗方法尚无定论。重复内镜下尿道切开术可打开狭窄部位,但通常在2年内会再次瘢痕化,需要重复手术。开放性尿道成形术则需要通过手术重建尿道,可能需要口腔黏膜移植。这是一种专科手术,恢复期较长,但复发风险可能较低。在缺乏确凿证据表明哪种方法最佳的情况下,个体男性必须权衡每种选择的侵入性和可能的益处。他们的偏好将受到个人社会环境、当地专业知识的可及性以及临床医生指导的影响。开放性尿道成形术与内镜下尿道切开术(OPEN)试验旨在通过比较2年内症状控制情况和进一步治疗需求方面的益处,更好地指导复发性尿道狭窄男性的治疗选择。
方法/设计:OPEN是一项务实的英国多中心随机试验。患有复发性球部尿道狭窄(至少接受过一次先前治疗)的男性将被随机分配接受内镜下尿道切开术或开放性尿道成形术。随机分组后,将对参与者进行24个月的随访,测量症状、尿流率、再次干预的需求、健康相关生活质量和成本。主要临床结局是通过有效评分曲线下面积(AUC)测量的24个月内症状控制的差异。该试验的检验效能为90%,I型错误率为5%,以检测在0 - 1量表上测量的AUC有0.1的差异。分析将基于所有随机分组的参与者(意向性分析)。主要经济结局是每质量调整生命年的增量成本。一项定性研究将评估参与随机分组的意愿,从而评估招募入试验的能力。
OPEN试验旨在阐明目前复发性球部尿道狭窄手术治疗选择的相对益处,这些选择在侵入性和所需资源方面存在差异。我们的可行性研究发现,参与度将受到患者偏好以及普通泌尿外科医生和专科泌尿外科医生不同招募方式的限制。我们制定并实施了有效的策略来解决这些问题,特别是通过尽可能在接近诊断时邀请参与。此外,随着招募进展重新计算样本量,鉴于目标人群有限和资金限制,实现了更有效的设计。目前招募工作已按目标进行。
ISRCTN98009168 注册日期:2012年11月29日。